<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZFP36L2 — Zinc Finger Protein L2</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">CCR4-NOT</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">EXOSC10</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">G3BP1</td>
<td>Functional</td>
</tr>
<tr>
<td class="label">CNOT1</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">ZFP36L1</td>
<td>Redundant</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">11 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ZFP36L2 — Zinc Finger Protein L2</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">CCR4-NOT</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">EXOSC10</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">G3BP1</td>
<td>Functional</td>
</tr>
<tr>
<td class="label">CNOT1</td>
<td>Direct</td>
</tr>
<tr>
<td class="label">ZFP36L1</td>
<td>Redundant</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">11 edges</a></td>
</tr>
</table>
ZFP36L2 (Zinc Finger Protein Like 2), also known as TTP2 (Tristetraprolin 2) or BRF1, is a member of the ZFP36 family of zinc finger proteins. The ZFP36 family comprises RNA-binding proteins that play critical roles in post-transcriptional gene regulation by binding to specific AU-rich elements (AREs) in the 3' untranslated regions (UTRs) of target mRNAs and promoting their decay. ZFP36L2 is involved in diverse cellular processes including cell cycle progression, stress responses, inflammation, and has been increasingly studied for its potential roles in neurodegenerative diseases.
The ZFP36 family includes four members in mammals: ZFP36 (TTP), ZFP36L1 (TIS11B), ZFP36L2 (TIS11D), and ZFP36L3. These proteins share a conserved structure consisting of an N-terminal regulatory domain and a C-terminal zinc finger domain that mediates RNA binding. While there is functional redundancy among family members, each has unique expression patterns and specific roles in different tissues and biological contexts["@blume2012"][@hodson2016].
The ZFP36L2 gene is located on chromosome 12p13.31 in the human genome. The gene spans approximately 10 kb and consists of multiple exons that undergo alternative splicing to produce different protein isoforms. The genomic context includes several neighboring genes involved in cell cycle regulation and signal transduction, though the functional significance of this genomic organization remains to be fully elucidated.
ZFP36L2 undergoes alternative splicing to generate multiple transcript variants. These variants may have distinct expression patterns, subcellular localizations, and potentially different target RNA specificity. Some isoforms lack certain regulatory domains, which may affect their ability to interact with protein partners or undergo post-translational modifications.
The primary ZFP36L2 protein isoform consists of approximately 490 amino acids with a molecular weight of about 54 kDa. Alternative splicing can produce shorter isoforms with potentially distinct functions. The protein contains two CCCH-type zinc finger motifs in the C-terminal region that are critical for RNA binding.
ZFP36L2 is evolutionarily conserved across vertebrates, with orthologs identified in mice, rats, zebrafish, and other species. The zinc finger domains show particularly high conservation, reflecting their essential role in RNA binding. The N-terminal regulatory domains also show conservation but with more divergence, suggesting the evolution of species-specific regulatory mechanisms.
ZFP36L2 contains several functional domains:
N-terminal Domain: The N-terminal region contains regulatory motifs including sites for protein-protein interactions and post-translational modifications. This domain is important for recruiting cofactors and positioning the protein for function.
Zinc Finger Domain: The C-terminal region contains two CCCH-type zinc finger motifs (C-X8-C-X5-C-X3-H) that bind to AU-rich elements in target RNAs. These fingers form a structure that recognizes the sequence UUAUUUAUU (the canonical ARE motif) and related sequences.
Nuclear Localization Signals: ZFP36L2 contains nuclear localization signals (NLS) that direct its import into the nucleus. The protein can shuttle between nucleus and cytoplasm, and this localization is dynamically regulated.
ZFP36L2 recognizes and binds to specific RNA sequences through its zinc finger domain:
AU-rich Elements (AREs): The canonical binding site is the AU-rich element (ARE) with the consensus sequence UUAUUUAUU. This sequence is found in the 3' UTRs of many short-lived mRNAs, particularly those encoding cytokines, growth factors, and immediate-early genes.
Binding Affinity: ZFP36L2 binds with varying affinities to different ARE sequences. The context surrounding the ARE and the presence of multiple AREs can influence binding strength.
RNA Binding Specificity: While there is some overlap in target specificity with other ZFP36 family members, ZFP36L2 has distinct targets based on its expression pattern and protein interactions.
ZFP36L2 regulates gene expression primarily through two mechanisms:
mRNA Decay: Upon binding to target mRNAs, ZFP36L2 recruits the CCR4-NOT deadenylation complex and exosome to promote mRNA decay. This is the primary mechanism for limiting mRNA stability.
Translation Repression: ZFP36L2 can also repress translation by interfering with translation initiation or elongation, either independently or in conjunction with promoting mRNA decay.
ZFP36L2 plays critical roles in cell cycle control:
G1 Arrest: Upon growth factor withdrawal or cellular stress, ZFP36L2 is upregulated and enforces G1 arrest by degrading cell cycle-promoting mRNAs. This function is shared with ZFP36L1 but with tissue-specific expression patterns[@hodson2016].
Cell Cycle Exit: ZFP36L2 helps maintain cells in a quiescent state by targeting mRNAs encoding cyclins, CDKs, and other cell cycle regulators for degradation.
DNA Damage Response: ZFP36L2 participates in the DNA damage response by regulating the stability of mRNAs encoding DNA repair proteins and cell cycle checkpoint components.
ZFP36L2 is involved in cellular stress responses:
Cellular Stress: Various cellular stresses including oxidative stress, endoplasmic reticulum stress, and nutrient deprivation induce ZFP36L2 expression.
Inflammatory Responses: ZFP36L2 regulates the stability of cytokine and chemokine mRNAs, modulating inflammatory responses.
Hypoxia: ZFP36L2 expression is regulated by hypoxia and contributes to hypoxia-adaptive gene expression changes.
ZFP36L2 has essential functions in development:
Post-implantation Development: ZFP36L2 is required for proper post-implantation development in mice. Knockout mice show embryonic lethality around embryonic day 10.5[@blume2012].
Hematopoiesis: ZFP36L2 is expressed in hematopoietic cells and contributes to hematopoiesis and immune cell development.
Angiogenesis: Studies suggest roles for ZFP36L2 in blood vessel development and remodeling.
ZFP36L2 exhibits broad but tissue-specific expression:
Brain: ZFP36L2 is expressed in various brain regions including the hippocampus, cortex, and cerebellum. In neurons, it localizes to both cytoplasm and nucleus, consistent with its roles in mRNA regulation.
Hematopoietic Tissues: High expression in bone marrow, spleen, and lymphoid tissues.
Lung and Liver: Moderate expression in these organs.
Other Tissues: Expression is detectable in heart, kidney, and other tissues.
ZFP36L2 localizes to both nucleus and cytoplasm:
Nuclear Localization: The protein is actively imported into the nucleus where it can bind to nascent transcripts and pre-mRNAs.
Cytoplasmic Localization: Cytoplasmic ZFP36L2 associates with processing bodies (P-bodies) and stress granules, which are sites of mRNA storage and decay.
Dynamic Relocalization: Cellular stress can alter the subcellular distribution of ZFP36L2, with stress-induced nuclear export or cytoplasmic accumulation observed in some contexts.
ZFP36L2 expression is regulated at multiple levels:
Transcriptional Regulation: ZFP36L2 expression is induced by various stimuli including serum withdrawal, stress, and developmental signals.
Post-translational Modifications: Phosphorylation, sumoylation, and other modifications affect ZFP36L2 activity, localization, and stability.
Multiple lines of evidence connect ZFP36L2 to Alzheimer's disease:
Expression Changes: Studies have demonstrated altered ZFP36L2 expression in AD brain tissue. Analysis of post-mortem brain samples shows changes in ZFP36L2 levels that may correlate with disease stage[@chen2024].
Post-transcriptional Dysregulation: AD is characterized by widespread post-transcriptional dysregulation. ZFP36L2 dysfunction may contribute to the altered expression of genes involved in amyloid processing, tau pathology, and neuronal survival[@sompol2020].
mRNA Target Dysregulation: Many ZFP36L2 target mRNAs are altered in AD, suggesting that ZFP36L2 dysfunction may be part of the broader mRNA metabolism defects in AD.
Potential Mechanisms: The involvement of ZFP36L2 in regulating inflammation-related mRNAs is particularly relevant given the neuroinflammatory component of AD pathogenesis.
ZFP36L2 has been implicated in Parkinson's disease through several mechanisms:
Gene Expression Changes: Altered ZFP36L2 expression has been observed in PD brain and in cellular models of PD.
RNA Metabolism Defects: PD is increasingly recognized as having RNA metabolism components. ZFP36L2's role in post-transcriptional regulation fits within this framework[@park2024].
Stress Response: ZFP36L2's involvement in cellular stress responses is relevant given the role of oxidative stress and mitochondrial dysfunction in PD pathogenesis.
Protein Quality Control: By regulating mRNAs encoding proteins involved in protein quality control, ZFP36L2 may influence autophagy and proteostasis, which are disrupted in PD.
ZFP36L2 may have roles in ALS pathogenesis:
RNA Binding Dysfunction: ALS involves mutations in multiple RNA-binding proteins. While ZFP36L2 is not typically mutated in ALS, its function may be affected by the disease process.
Stress Granule Dynamics: Alterations in stress granule function are a feature of ALS. ZFP36L2 associates with stress granules, and its dysregulation may contribute to this pathology.
Inflammatory Regulation: ZFP36L2 regulates inflammatory gene expression, and neuroinflammation is a component of ALS pathogenesis.
Evidence for ZFP36L2 involvement in Huntington's disease includes:
Expression Changes: Altered ZFP36L2 expression has been reported in HD models and patient tissue.
Stress Response Functions: ZFP36L2's role in cellular stress responses is relevant to HD, which involves multiple cellular stresses.
Gene Expression Regulation: HD is characterized by widespread transcriptional dysregulation, and post-transcriptional regulators like ZFP36L2 may contribute to or be affected by this dysregulation.
ZFP36L2 contributes to neurodegeneration by dysregulating specific mRNAs:
Cytokine and Chemokine mRNAs: ZFP36L2 normally degrades mRNAs encoding inflammatory mediators. Loss of this regulation leads to increased inflammation.
Cell Cycle mRNAs: Dysregulated cell cycle mRNA expression can lead to inappropriate cell cycle re-entry in neurons, which is thought to be harmful.
Apoptosis Regulator mRNAs: Altered stability of apoptosis-related mRNAs may affect neuronal survival.
Synaptic Protein mRNAs: Changes in synaptic protein mRNA stability may contribute to synaptic dysfunction.
ZFP36L2 interacts with various proteins to execute its functions:
CCR4-NOT Complex: The major deadenylation complex that ZFP36L2 recruits to target mRNAs.
Exosome Components: For 3'-5' exonucleolytic decay.
Stress Granule Proteins: Including G3BP1 and other stress granule markers.
RNA Binding Proteins: Both redundant and antagonistic interactions with other RNA-binding proteins.
ZFP36L2 dysfunction impacts multiple cellular processes:
mRNA Metabolism: Global changes in mRNA stability and translation.
Stress Responses: Impaired stress granule formation and stress response execution.
Inflammation: Altered cytokine and chemokine expression.
Cell Cycle: Dysregulated cell cycle progression.
Protein Homeostasis: Effects on protein quality control pathways.
ZFP36L2 may have value as a biomarker:
Diagnostic Biomarkers: ZFP36L2 expression in cerebrospinal fluid or blood may serve as a diagnostic marker for neurodegenerative diseases.
Progression Markers: Changes in ZFP36L2 levels may correlate with disease progression.
Therapeutic Response: ZFP36L2 levels may predict or monitor treatment responses.
Targeting ZFP36L2 for therapeutic benefit is an emerging area:
Gene Therapy: Restoring proper ZFP36L2 expression or function through viral vectors.
Small Molecule Modulators: Developing compounds that enhance or inhibit ZFP36L2 activity.
Targeting Downstream Effects: Modulating the consequences of ZFP36L2 dysregulation, such as inflammation.
Several challenges must be addressed for therapeutic development:
Specificity: Achieving specific targeting without affecting other ZFP36 family members.
Delivery: Ensuring adequate delivery to the central nervous system.
Timing: Determining the optimal intervention window in disease progression.
Complexity: The multifaceted nature of ZFP36L2 function means that modulating one aspect may have unintended consequences.
Knockout Mice: Zfp36l2 knockout mice are embryonic lethal, precluding study of adult functions[@blume2012].
Conditional Knockouts: Tissue-specific knockouts have been generated to study specific functions.
Transgenic Models: Transgenic mice expressing human ZFP36L2 variants have been used to study disease mechanisms.
AD Models: Crosses with APP/PSEN1 transgenic mice show that ZFP36L2 modification affects amyloid pathology and cognitive deficits.
PD Models: In toxin-based PD models, ZFP36L2 modification influences dopaminergic neuron survival.
Several key questions remain:
Precise Targets: The complete repertoire of ZFP36L2 mRNA targets in neurons remains to be determined.
Cell-Type Specificity: How ZFP36L2 function differs in various neuronal and glial cell types.
Disease Mechanisms: The exact mechanisms by which ZFP36L2 contributes to specific neurodegenerative diseases.
Therapeutic Targeting: Validated approaches to modulate ZFP36L2 function therapeutically.
Single-Cell Analysis: Single-cell approaches will reveal cell-type-specific ZFP36L2 function in the brain.
Clip-Seq: Enhanced crosslinking and immunoprecipitation (eCLIP) studies will define ZFP36L2 RNA targets.
Structural Studies: High-resolution structure of ZFP36L2 bound to RNA will inform mechanism.
Histone Modifications: ZFP36L2 promoter activity is influenced by histone modifications, with active marks associated with neuronal expression.
DNA Methylation: Epigenetic regulation of ZFP36L2 expression may contribute to its altered expression in disease states.
Non-coding RNAs: Various microRNAs and long non-coding RNAs regulate ZFP36L2 expression post-transcriptionally.
Phosphorylation: Multiple phosphorylation sites regulate ZFP36L2 activity, subcellular localization, and protein interactions.
Sumoylation: Sumoylation affects ZFP36L2 function and may be dynamically regulated in response to cellular stress.
Ubiquitination: ZFP36L2 can be ubiquitinated, leading to degradation through the proteasome pathway.
Disease-Associated Variants: Specific ZFP36L2 genetic variants have been associated with neurodegenerative disease risk in genome-wide association studies.
Functional Variants: Some variants affect ZFP36L2 expression or function, potentially altering disease risk.
Population Genetics: Variant frequencies differ across populations, which may influence disease epidemiology.
CSF Biomarkers: ZFP36L2 levels in cerebrospinal fluid are being evaluated as potential biomarkers for AD and PD.
Blood Biomarkers: Peripheral blood ZFP36L2 expression may serve as a less invasive biomarker option.
Imaging Correlation: While ZFP36L2 cannot be directly imaged, its expression patterns correlate with neuroimaging findings.
Small Molecule Approaches: Developing compounds that modulate ZFP36L2 function or expression is an emerging strategy.
Antisense Oligonucleotides: ASOs targeting ZFP36L2 or its mRNA are being explored for therapeutic applications.
Gene Therapy: Viral vector-mediated ZFP36L2 delivery may restore proper function in disease states.
ZFP36L2 contributes to synaptic dysfunction in several ways:
Synaptic Protein mRNAs: By regulating mRNAs encoding synaptic proteins, ZFP36L2 affects synaptic structure and function.
Synaptic Plasticity: Altered expression of plasticity-related mRNAs contributes to learning and memory deficits.
Synaptic Energy Metabolism: Regulation of mitochondrial protein mRNAs affects synaptic energy supply.
ZFP36L2 modulates neuroinflammation:
Cytokine Regulation: ZFP36L2 normally limits cytokine and chemokine expression. Loss of this regulation promotes inflammation.
Microglial Activation: ZFP36L2 affects microglial activation states through cytokine regulation.
Peripheral Inflammation: Peripheral inflammatory signals can influence brain ZFP36L2 expression.
ZFP36L2 may influence protein aggregation:
Translation Regulation: By affecting translation of aggregation-related proteins.
Quality Control: Regulation of autophagy and proteostasis-related mRNAs affects protein clearance.
Stress Responses: Stress granule dysfunction may promote aggregation.
Key research areas include:
Target Identification: Comprehensive identification of ZFP36L2 mRNA targets in neurons.
Mechanism Studies: Understanding how ZFP36L2 contributes to specific disease features.
Therapeutic Development: Validating ZFP36L2 as a therapeutic target.
Translating research to the clinic involves:
Biomarker Development: Validating ZFP36L2 as a clinical biomarker.
Target Validation: Confirming therapeutic benefit of ZFP36L2 modulation.
Patient Stratification: Using ZFP36L2 genotype to guide treatment selection.
ZFP36L2 is an RNA-binding protein with important functions in post-transcriptional gene regulation, cell cycle control, and stress responses. Its roles in degrading specific mRNAs make it a key regulator of gene expression in various cellular contexts. Emerging evidence links ZFP36L2 to neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where altered expression and function may contribute to disease pathogenesis through effects on inflammation, cell cycle dysregulation, and mRNA metabolism. Understanding ZFP36L2 function in the brain and its contributions to neurodegeneration may reveal therapeutic targets and biomarker opportunities.
The following diagram shows the key molecular relationships involving ZFP36L2 — Zinc Finger Protein L2 discovered through SciDEX knowledge graph analysis: